Drugs / biphasic insulin aspart 70
biphasic insulin aspart 70
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT01538511 | Jun 2006 → Mar 2007 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT01536028 | Apr → Jul 2006 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT01524809 | Jan → Jun 2001 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT01520831 | Apr 1999 → May 2000 | diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01526980 | May → Nov 2002 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | biphasic insulin aspart 70 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01526980 ↗ |
| Known as | BIAsp 70 | “BIAsp 70 (70% insulin aspart and 30% protamine-complexed insulin aspart) before breakfast and lunch” PMID 19527481 ↗ Jul 20091“The new formulations BIAsp 50 and BIAsp 70 contain 50% and 70% soluble IAsp, respectively.” PMID 19049377 ↗ Dec 2008 |
| Known as | NN2000-Mix70 | “A Two-centre, Randomised, Open-labelled, Four-week, Parallel-group Pharmacokinetics Trial in Japanese Type 2 Diabetic Subjects Characterising the Insulin Profile of Thrice...” NCT01538511 ↗ |
| Route | Subcutaneous | “Administrated subcutaneously (s.c., under the skin)” NCT01524809 ↗ |